Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome

Iuorno, Maria J.; Jakubowicz, Daniela J.; Baillargeon, Jean-Patrice; Dillon, Pamela; Gunn, Ronald D.; Allan, Geoffrey; Nestler, John E.

doi:10.4158/ep.8.6.417

Cited by 188Ovarian function and disordersDiabetes, Cardiovascular Risks, and LipoproteinsGenetic and Kidney Cyst Diseases

Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome

Iuorno, Maria J., Jakubowicz, Daniela J., Baillargeon, Jean-Patrice, Dillon, Pamela, Gunn, Ronald D., Allan, Geoffrey, Nestler, John E.·2002·Endocrine Practice

DOI 10.4158/ep.8.6.417

Open this paper in CoChat — free account

Abstract

Objective To determine whether the administration of D-chiro-inositol, a putative insulin-sensitizing drug, would affect the concentration of circulating insulin, the levels of serum androgens, and the frequency of ovulation in lean women with the polycystic ovary syndrome.Methods In 20 lean women (body mass index, 20.0 to 24.4 kg/m 2) who had the polycystic ovary syndrome, treatment was initiated with either 600 mg of D-chiro-inositol or placebo orally once daily for 6 to 8 weeks. We performed oral glucose tolerance tests and measured serum sex steroids before and after therapy. To monitor for ovulation, we determined serum progesterone concentrations weekly.Results In the 10 women given D-chiro-inositol, the mean (+/- standard error) area under the plasma insulin curve after oral administration of glucose decreased significantly from 8,343 +/- 1,149 mU/mL per min to 5,335 +/- 1,792 mU/mL per min in comparison with no significant change in the placebo group (P = 0.03 for difference between groups). Concomitantly, the serum free testosterone concentration decreased by 73% from 0.83 +/- 0.11 ng/dL to 0.22 +/- 0.03 ng/dL, a significant change in comparison with essentially no change in the placebo group (P = 0.01). Six of the 10 women (60%) in the D-chiro-inositol group ovulated in comparison with 2 of the 10 women (20%) in the placebo group (P = 0.17). Systolic (P = 0.002) and diastolic (P = 0.001) blood pressures, as well as plasma triglyceride concentrations (P = 0.001), decreased significantly in the D-chiro-inositol group in comparison with the placebo group, in which these variables either increased (blood pressure) or decreased minimally (triglycerides).Conclusion We conclude that, in lean women with the polycystic ovary syndrome, D-chiro-inositol reduces circulating insulin, decreases serum androgens, and ameliorates some of the metabolic abnormalities (increased blood pressure and hypertriglyceridemia) of syndrome X.

Integrity signals

Registry

Crossref · 10.4158/ep.8.6.417

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Two included studies trialed DCI alone.
“Two studies trialed DCI alone (35, 43).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [35]
Three included studies were placebo controlled.
“Three studies were placebo controlled (32, 35, 43).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [35]
Sample sizes in the two DCI vs placebo trials were 20 and 44.
“Two trials reported on this comparison (35, 43). Sample sizes were 20 and 44.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [35]
Two trials reported on the DCI vs placebo comparison.
“Two trials reported on this comparison (35, 43). Sample sizes were 20 and 44.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [35]
The dose of DCI provided in the DCI vs placebo trials ranged from 600 mg to 1.2 g daily.
“The dose of DCI provided ranged from 600 mg (35) to 1.2 g (43) daily.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [35]

Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154 · see citing works
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · see citing works
Polycystic Ovary Syndrome
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463 · see citing works
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · see citing works
Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature
Södergard, R., Bäckström, T., Shanbhag, V., & Carstensen, H. (1982) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(82)90038-3 · Cited by 1,080 · see citing works
Effects of Metformin on Spontaneous and Clomiphene-Induced Ovulation in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Evans, W. S., & Pasquali, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806253382603 · Cited by 781 · see citing works
Decreases in Ovarian Cytochrome P450c17α Activity and Serum Free Testosterone after Reduction of Insulin Secretion in Polycystic Ovary Syndrome
Nestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743 · see citing works
Insulin resistance in nonobese patients with polycystic ovarian disease
CHANG, R. J., NAKAMURA, R. M., JUDD, H. L., & KAPLAN, S. A. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-2-356 · Cited by 704 · see citing works
Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome.
Dunaif, A., Xia, J., Book, C. B., Schenker, E., & Tang, Z. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118126 · Cited by 561 · see citing works
The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
Dunaif, A. E., Scott, D., Finegood, D. T., Quintana, B., & Whitcomb, R. W. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.9.8784087 · Cited by 560 · see citing works
Evidence for Distinctive and Intrinsic Defects in Insulin Action in Polycystic Ovary Syndrome
Dunaif, A. E., Segal, K. R., Shelley, D., Green, G., Dobrjansky, A., & Licholai, T. (1992) · Diabetes · doi:10.2337/diab.41.10.1257 · Cited by 544 · see citing works
Troglitazone Improves Ovulation and Hirsutism in the Polycystic Ovary Syndrome: A Multicenter, Double Blind, Placebo-Controlled Trial1
Azziz, R., Ehrmann, D. A., Legro, R. S., Whitcomb, R. W., Hanley, R. M., Fereshetian, A. G., O’Keefe, M., & Ghazzi, M. N. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7375 · Cited by 537 · see citing works
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · see citing works
Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome1
Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461 · see citing works
Lean Women with Polycystic Ovary Syndrome Respond to Insulin Reduction with Decreases in Ovarian P450c17 Activity and Serum Androgens
Nestler, J. E., & Jakubowicz, D. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4431 · Cited by 394 · see citing works
Troglitazone Improves Ovulation and Hirsutism in the Polycystic Ovary Syndrome: A Multicenter, Double Blind, Placebo-Controlled Trial
Azziz, R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.4.1626 · Cited by 378 · see citing works
Cellular mechanisms of insulin resistance in polycystic ovarian syndrome
Ciaraldi, T. P. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.2.577 · Cited by 336 · see citing works
Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome
Diamanti‐Kandarakis, E., Kouli, C., Tsianateli, T. C., & Bergiele, A. T. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1380269 · Cited by 320 · see citing works
chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects.
Asplin, I., Galasko, G. T., & Larner, J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.5924 · Cited by 169 · see citing works
Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion
Geffner, M. E., Kaplan, S. A., Bersch, N., Golde, D. W., Landaw, E. M., & Chang, R. J. (1986) · Fertility and Sterility · doi:10.1016/s0015-0282(16)49211-3 · Cited by 156 · see citing works
Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance–related polycystic ovary syndrome
Hasegawa, I., Murakawa, H., Suzuki, M., Yamamoto, Y., Kurabayashi, T., & Tanaka, K. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00454-3 · Cited by 156 · see citing works
Polycystic ovarian disease: US features in 104 patients.
Yeh, H., Futterweit, W., & Thornton, J. C. (1987) · Radiology · doi:10.1148/radiology.163.1.3547491 · Cited by 140 · see citing works
Impact of Obesity on Insulin Action in Volunteers with Normal Glucose Tolerance: Demonstration of a Threshold for the Adverse Effect of Obesity*
CAMPBELL, P. J., & Gerich, J. E. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-4-1114 · Cited by 137 · see citing works
Lean Women With Polycystic Ovary Syndrome Respond to Insulin Reduction With Decreases in Ovarian P450c17 alpha Activity and Serum Androgens
Nestler, J. E., & Jakubowicz, D. J. (1998) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199805000-00018 · Cited by 135 · see citing works
Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women With Polycystic Ovary Syndrome
Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1998) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199801000-00017 · Cited by 129 · see citing works
Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys.
Ortmeyer, H. K., Huang, L. C., Zhang, L., Hansen, B. C., & Larner, J. (1993) · Endocrinology · doi:10.1210/endo.132.2.8425484 · Cited by 113 · see citing works
Insulin-sensitizing agents in polycystic ovary syndrome
Pasquali, R., & Gambineri, A. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02156 · Cited by 112 · see citing works
Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys
Ortmeyer, H. K., Bodkin, N. L., Lilley, K., Larner, J., & HANSEN, B. C. (1993) · Endocrinology · doi:10.1210/endo.132.2.8425483 · Cited by 96 · see citing works
Urinary chiro-Inositol Excretion is an Index Marker of Insulin Sensitivity in Japanese Type II Diabetes
Suzuki, S., Kawasaki, H., Sato, Y., Ohtomo, M., Hirai, M., Hirai, A. M., Hirai, S., Onoda, M., Matsumoto, M., Hinokio, Y., et al. (1994) · Diabetes Care · doi:10.2337/diacare.17.12.1465 · Cited by 84 · see citing works
Insulin Mediators Are the Signal Transduction System Responsible for Insulin’s Actions on Human Placental Steroidogenesis*
Nestler, J. E., Romero, G. G., HUANG, L. C., ZHANG, C., & Larner, J. (1991) · Endocrinology · doi:10.1210/endo-129-6-2951 · Cited by 50 · see citing works
The Insulin-Sensitizing Agent Troglitazone Improves Metabolic and Reproductive Abnormalities in the Polycystic Ovary Syndrome
Dunaif, A. E., Scott, D., Finegood, D. T., Quintana, B., & Whitcomb, R. W. (1997) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199702000-00016 · Cited by 32 · see citing works
Insulin sensitizing agents and polycystic ovary syndrome
Pasquali, R., & Filicori, M. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1380253 · Cited by 13 · see citing works

Flagged first, then by citations

1 of the 33 references couldn’t be matched to a known paper.

Sorted by citations

Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041454 · Cited by 521 · see citing works
Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome
Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221 · see citing works
RETRACTED: Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · see citing works
Retracted
The “Other” Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo ‐Inositol Chemistry)
THOMAS, M. P., Mills, S. J., & Potter, B. V. L. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201502227 · Cited by 190 · see citing works
Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction
Papaleo, E., Unfer, V., Baillargeon, J., Santis, L. D., Fusi, F., Brigante, C., Marelli, G., Cino, I., Redaelli, A., & Ferrari, A. G. (2007) · Gynecological Endocrinology · doi:10.1080/09513590701672405 · Cited by 186 · see citing works
Antioxidants for female subfertility
Showell, M. G., Brown, J., Clarke, J., & Hart, R. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007807.pub2 · Cited by 188 · see citing works
A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills
Diamanti‐Kandarakis, E., Baillargeon, J., Iuorno, M. J., Jakubowicz, D. J., & Nestler, J. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021528 · Cited by 168 · see citing works
Untitled work
(2009) · PubMed · Cited by 160 · see citing works
Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study
Artini, P. G., Di Berardino, O. M., Papini, F., Genazzani, A. D., Simi, G., Ruggiero, M., & Cela, V. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.743020 · Cited by 154 · see citing works
Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials
Unfer, V., Nestler, J. E., Kamenov, Z. A., Prapas, N., & Facchinetti, F. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1849162 · Cited by 151 · see citing works
Altered D-Chiro-Inositol Urinary Clearance in Women With Polycystic Ovary Syndrome
Baillargeon, J., Diamanti‐Kandarakis, E., Ostlund, R. E., Apridonidze, T., Iuorno, M. J., & Nestler, J. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1070 · Cited by 147 · see citing works
Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143 · see citing works
“Iuorno, 2002 [39] Venezuela NR 10/10 27.”
Antioxidants for female subfertility
Showell, M. G., Mackenzie-Proctor, R., Jordan, V., & Hart, R. J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007807.pub4 · Cited by 119 · see citing works
Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta‐analysis of randomised trials
Pundir, J., Psaroudakis, D., Savnur, P., Bhide, P., Sabatini, L., Teede, H., Coomarasamy, A., & Thangaratinam, S. (2018) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.14754 · Cited by 115 · see citing works
Untitled work
(2012) · PubMed · Cited by 111 · see citing works
Reflections on inositol(s) for PCOS therapy: steps toward success
Nestler, J. E., & Unfer, V. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1054802 · Cited by 106 · see citing works
Inositol as putative integrative treatment for PCOS
Genazzani, A. D. (2016) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2016.08.024 · Cited by 106 · see citing works
Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
Raffone, E., Rizzo, P., & Benedetto, V. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903366996 · Cited by 100 · see citing works
Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice
Croze, M. L., Vella, R., Pillon, N. J., Soula, H. A., Hadji, L., Guichardant, M., & Soulage, C. O. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.01.008 · Cited by 97 · see citing works
Rat L6 myotubes as an in vitro model system to study GLUT4-dependent glucose uptake stimulated by inositol derivatives
Yap, A., Nishiumi, S., Yoshida, K., & Ashida, H. (2007) · Cytotechnology · doi:10.1007/s10616-007-9107-y · Cited by 96 · see citing works
The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome
Dinicola, S., Chiu, T. T. Y., Unfer, V., Carlomagno, G., & Bizzarri, M. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.362 · Cited by 95 · see citing works
Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome
Zacchè, M. M., Caputo, L., Filippis, S., Zacchè, G., Dindelli, M., & Ferrari, A. G. (2009) · Gynecological Endocrinology · doi:10.1080/09513590903015544 · Cited by 91 · see citing works
Comparison between effects of myo-inositol and<scp>d</scp>-chiro-inositol on ovarian function and metabolic factors in women with PCOS
Pizzo, A., Laganà, A. S., & Barbaro, L. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2013.860120 · Cited by 90 · see citing works
Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome
Donà, G., Sabbadin, C., Fiore, C., Bragadin, M., Giorgino, F. L., Ragazzi, E., Clari, G., Bordin, L., & Armanini, D. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0840 · Cited by 89 · see citing works
Inositol’s and other nutraceuticals’ synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives
Paul, C. I., Laganà, A. S., Maniglio, P., Triolo, O., & Brady, D. M. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2016.1144741 · Cited by 89 · see citing works
Effects of myoinositol on sperm mitochondrial function in-vitro.
Condorelli, R. A., Vignera, S. L., Bari, F. D., Unfer, V., & Calogero, A. E. (2011) · PubMed · Cited by 85 · see citing works
Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology – assisted reproduction technology
Bevilacqua, A., Carlomagno, G., Gerli, S., Oliva, M. M., Devroey, P., Lanzone, A., Soulage, C. O., Facchinetti, F., Renzo, G. C. D., Bizzarri, M., et al. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1006616 · Cited by 83 · see citing works
Antioxidants for female subfertility
Showell, M. G., Mackenzie-Proctor, R., Jordan, V., & Hart, R. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007807.pub3 · Cited by 83 · see citing works
Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study
Calogero, A. E., Gullo, G., Vignera, S. L., Condorelli, R. A., & Vaiarelli, A. (2015) · Andrology · doi:10.1111/andr.12025 · Cited by 81 · see citing works
Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance
Kamenov, Z. A., Kolarov, G., Gateva, A., Carlomagno, G., & Genazzani, A. D. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2014.964640 · Cited by 80 · see citing works
Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol
Sacchi, S., Marinaro, F., Tondelli, D., Lui, J., Xella, S., Marsella, T., Tagliasacchi, D., Argento, C., Tirelli, A., Giulini, S., et al. (2016) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-016-0189-2 · Cited by 78 · see citing works
Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism
Baillargeon, J., Nestler, J. E., Ostlund, R. E., Apridonidze, T., & Diamanti‐Kandarakis, E. (2008) · Human Reproduction · doi:10.1093/humrep/den097 · Cited by 77 · see citing works
Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature
Regidor, P., Schindler, A. E., Lesoine, B., & Druckman, R. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0067 · Cited by 76 · see citing works
Inositol for subfertile women with polycystic ovary syndrome
Showell, M. G., Mackenzie-Proctor, R., Jordan, V., Hodgson, R., & Farquhar, C. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012378.pub2 · Cited by 76 · see citing works
Metformin Therapy Increases Insulin-Stimulated Release of d -Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome
Baillargeon, J., Iuorno, M. J., Jakubowicz, D. J., Apridonidze, T., He, N., & Nestler, J. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030437 · Cited by 74 · see citing works
Uncoupling Between Insulin and Release of a d - Chiro -Inositol–Containing Inositolphosphoglycan Mediator of Insulin Action in Obese Women With Polycystic Ovary Syndrome
Baillargeon, J., Iuorno, M. J., Apridonidze, T., & Nestler, J. E. (2010) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2009.0052 · Cited by 73 · see citing works
Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects
Baillargeon, J., & Carpentier, A. C. (2007) · Diabetologia · doi:10.1007/s00125-007-0831-9 · Cited by 72 · see citing works
RETRACTED ARTICLE: Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-Chiro-Inositol
Laganà, A. S., Barbaro, L., & Pizzo, A. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3552-6 · Cited by 71 · see citing works
Retracted
Inositol: history of an effective therapy for Polycystic Ovary Syndrome.
Bizzarri, M., & Carlomagno, G. (2014) · PubMed · Cited by 71 · see citing works
Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines
Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad762 · Cited by 70 · see citing works
“Fifteen trials were conducted in Italy (27, 29, 31-34, 38, 39, 44, 45, 47, 48, 50, 54, 55), 6 in India (26, 28, 30, 36, 41, 42, 51), 2 in Iran (25, 49), 2 in Venezuela (35, 43), and 1 each in Pakistan (37), Turkey (46), Spain (40), Denmark (52), and Bosnia and Herzegovina (53).”
Background
Inositol and human reproduction. From cellular metabolism to clinical use
Milewska, E. M., Czyzyk, A., Meczekalski, B., & Genazzani, A. D. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1188282 · Cited by 69 · see citing works
Combining treatment with myo-inositol and D -chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients
Monastra, G., Unfer, V., Harrath, A. H., & Bizzarri, M. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1247797 · Cited by 71 · see citing works
Nutritional supplements and herbal medicines for women with polycystic ovary syndrome; a systematic review and meta-analysis
Arentz, S., Smith, C. A., Abbott, J. A., & Bensoussan, A. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-2011-x · Cited by 69 · see citing works
Experts’ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond
Facchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63 · see citing works
Genetic Modification of Bacillus subtilis for Production of d - chiro -Inositol, an Investigational Drug Candidate for Treatment of Type 2 Diabetes and Polycystic Ovary Syndrome
Yoshida, K., Yamaguchi, M., Morinaga, T., Ikeuchi, M., Kinehara, M., & Ashida, H. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.72.2.1310-1315.2006 · Cited by 63 · see citing works
The metabolic profile of lemon juice by proton HR-MAS NMR: the case of the PGI Interdonato Lemon of Messina
Cicero, N., Corsaro, C., Salvo, A., Vasi, S., Giofrè, S. V., Ferrantelli, V., Stefano, V. A. D., Mallamace, D., & Dugo, G. (2015) · Natural Product Research · doi:10.1080/14786419.2015.1012166 · Cited by 63 · see citing works
Inositols and metabolic disorders: From farm to bedside
Caputo, M., Bona, E., Leone, I., Samà, M. T., Nuzzo, A., Ferrero, A., Aimaretti, G., Marzullo, P., & Prodam, F. (2020) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2020.03.005 · Cited by 60 · see citing works
Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis
Zeng, L., & Yang, K. (2018) · Endocrine · doi:10.1007/s12020-017-1442-y · Cited by 59 · see citing works
The inositols and polycystic ovary syndrome
Kalra, S., Kalra, B., & Sharma, J. B. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.189231 · Cited by 59 · see citing works
The effect of a combination therapy with myo-inositol and a combined oral contraceptive pillversusa combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome
Minozzi, M., Costantino, D., Guaraldi, C., & Unfer, V. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2011.564685 · Cited by 56 · see citing works
RETRACTED: Treatment of hirsutism with myo-inositol: a prospective clinical study
Minozzi, M., D'Andrea, G., & Unfer, V. (2008) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60248-9 · Cited by 56 · see citing works
Retracted
Inositols in the Treatment of Insulin-Mediated Diseases
Muscogiuri, G., Palomba, S., Laganà, A. S., & Orio, F. (2016) · International Journal of Endocrinology · doi:10.1155/2016/3058393 · Cited by 56 · see citing works
Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study
Lisi, F., Carfagna, P., Oliva, M. M., Rago, R., Lisi, R., Poverini, R., Manna, C., Vaquero, E., Caserta, D., Raparelli, V., et al. (2012) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-10-52 · Cited by 54 · see citing works
1H HR-MAS NMR Spectroscopy and the Metabolite Determination of Typical Foods in Mediterranean Diet
Corsaro, C., Mallamace, D., Vasi, S., Ferrantelli, V., Dugo, G., & Cicero, N. (2015) · Journal of Analytical Methods in Chemistry · doi:10.1155/2015/175696 · Cited by 52 · see citing works
The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review
Gateva, A., Unfer, V., & Kamenov, Z. A. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1421632 · Cited by 51 · see citing works
Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary
Roseff, S., & Montenegro, M. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6461254 · Cited by 52 · see citing works
Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS
Unfer, V., Dinicola, S., Laganà, A. S., & Bizzarri, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197157 · Cited by 51 · see citing works
HR-MAS and NMR towards Foodomics
Corsaro, C., Cicero, N., Mallamace, D., Vasi, S., Naccari, C., Salvo, A., Giofrè, S. V., & Dugo, G. (2016) · Food Research International · doi:10.1016/j.foodres.2016.09.033 · Cited by 50 · see citing works
Endometrium in women with polycystic ovary syndrome during the window of implantation
Lopes, I. M. R. S., Baracat, M. C. P., JesusSimões, M., Simões, R. S., Baracat, E. C., & Soares, J. M. (2011) · Revista da Associação Médica Brasileira (English Edition) · doi:10.1016/s2255-4823(11)70138-2 · Cited by 49 · see citing works
Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols
Sortino, M. A., Salomone, S., Carruba, M. O., & Drago, F. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00341 · Cited by 48 · see citing works
The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials
Tabrizi, R., Ostadmohammadi, V., Lankarani, K. B., Peymani, P., Akbari, M., Kolahdooz, F., & Asemi, Z. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0779-4 · Cited by 51 · see citing works
The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen
Morgante, G., Orvieto, R., Sabatino, A. D., Musacchio, M. C., & Leo, V. D. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.01.035 · Cited by 48 · see citing works
Inositol Treatment and ART Outcomes in Women with PCOS
Garg, D., & Tal, R. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1979654 · Cited by 47 · see citing works
<scp>d</scp>-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review
Galazis, N., Galazi, M., & Atiomo, W. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2010.538099 · Cited by 46 · see citing works
Green synthesis of biocompatible gold nanoparticles using Fagopyrum esculentum leaf extract
Babu, P. J., Sharma, P., Kalita, M. C., & Bora, U. (2011) · Frontiers of Materials Science · doi:10.1007/s11706-011-0153-1 · Cited by 46 · see citing works
Inositol and antioxidant supplementation: Safety and efficacy in pregnancy
Formoso, G., BALDASSARRE, M. P. A., Ginestra, F., Carlucci, M. A., Bucci, I., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3154 · Cited by 47 · see citing works
The menstrual cycle regularization following d -chiro-inositol treatment in PCOS women: a retrospective study
Marca, A. L., Grisendi, V., Dondi, G., Sighinolfi, G., & Cianci, A. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2014.964201 · Cited by 45 · see citing works
Endométrio na janela de implantação em mulheres com síndrome dos ovários policísticos
Lopes, J. M., Baracat, M. C. P., Simões, M. D. J., Simões, R. S., Baracat, E. C., & Soares, J. M. (2011) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302011000600020 · Cited by 42 · see citing works
Physiological role and clinical utility of inositols in polycystic ovary syndrome
Bevilacqua, A., & Bizzarri, M. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.03.007 · Cited by 42 · see citing works
A review of the role of inositols in conditions of insulin dysregulation and in uncomplicated and pathological pregnancy
Watkins, O. C., Yong, H. E. J., Sharma, N., & Chan, S. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1845604 · Cited by 40 · see citing works
Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial
Fraticelli, F., Celentano, C., Zecca, I. A., Di Vieste, G., Pintaudi, B., Liberati, M., Franzago, M., Di Nicola, M., & Vitacolonna, E. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1157-4 · Cited by 39 · see citing works
Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review
Bizzarri, M., Monti, N., Piombarolo, A., Angeloni, A., & Verna, R. (2023) · Nutrients · doi:10.3390/nu15081875 · Cited by 45 · see citing works
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36 · see citing works
Inositol supplementation and body mass index: A systematic review and meta‐analysis of randomized clinical trials
Zarezadeh, M., Dehghani, A., Faghfouri, A. H., Radkhah, N., Kermanshahi, M. N., Hamedi, F., Honarvar, N. M., Ghoreishi, Z., Ostadrahimi, A., & Ebrahimi‐Mameghani, M. (2021) · Obesity Science & Practice · doi:10.1002/osp4.569 · Cited by 34 · see citing works
Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action
Cicco, S. D., Immediata, V., Romualdi, D., Policola, C., Tropea, A., Florio, C. D., Tagliaferri, V., Scarinci, E., Casa, S. D., Lanzone, A., et al. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1313972 · Cited by 34 · see citing works
Prospective randomized trial of multiple micronutrients in subfertile women undergoing ovulation induction: a pilot study
Agrawal, R., Burt, E., Gallagher, A. M., Butler, L. M., Venkatakrishnan, R., & Peitsidis, P. (2011) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2011.10.004 · Cited by 34 · see citing works
PCOS and pregnancy: a review of available therapies to improve the outcome of pregnancy in women with polycystic ovary syndrome
Artini, P. G., Obino, M. E. R., Sergiampietri, C., Pinelli, S., Papini, F., Casarosa, E., & Cela, V. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1431122 · Cited by 33 · see citing works
Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials
Miñambres, I., Cuixart, G., Gonçalves, A., & Corcoy, R. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2018.06.957 · Cited by 33 · see citing works
Endometrium in women with polycystic ovary syndrome during the window of implantation
Lopes, I. M. R. S., Baracat, M. C. P., JesusSimões, M., Simões, R. S., Baracat, E. C., & Soares, J. M. (2011) · Revista da Associação Médica Brasileira · doi:10.1016/s0104-4230(11)70138-5 · Cited by 33 · see citing works
Inositol and In Vitro Fertilization with Embryo Transfer
Simi, G., Genazzani, A. R., Obino, M. E. R., Papini, F., Pinelli, S., Cela, V., & Artini, P. G. (2017) · International Journal of Endocrinology · doi:10.1155/2017/5469409 · Cited by 30 · see citing works
The effect of FT500 Plus® on ovarian stimulation in PCOS women
Alviggi, C., Cariati, F., Conforti, A., Rosa, P. D., Vallone, R., Strina, I., Pivonello, R., & Placido, G. D. (2015) · Reproductive Toxicology · doi:10.1016/j.reprotox.2015.10.014 · Cited by 29 · see citing works
Enhanced secretion of natto phytase by Bacillus subtilis
Tsuji, S., Tanaka, K., Takenaka, S., & Yoshida, K. (2015) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2015.1046366 · Cited by 29 · see citing works
The effectiveness of coenzyme Q10, vitamin E, inositols, and vitamin D in improving the endocrine and metabolic profiles in women with polycystic ovary syndrome: a network Meta-analysis
Zhang, J., Xing, C., Zhao, H., & He, B. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1926975 · Cited by 28 · see citing works
Prospective Randomized Study on the Influence of Myoinositol in PCOS Women Undergoing IVF in the Improvement of Oocyte Quality, Fertilization Rate, and Embryo Quality
Lesoine, B., & Regidor, P. (2016) · International Journal of Endocrinology · doi:10.1155/2016/4378507 · Cited by 26 · see citing works
Regulation of Inositol Biosynthesis: Balancing Health and Pathophysiology
Case, K. C., Salsaa, M., Yu, W., & Greenberg, M. L. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_181 · Cited by 22 · see citing works
New clinical targets of d -chiro-inositol: rationale and potential applications
Laganà, A. S., Garzon, S., & Unfer, V. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1785429 · Cited by 23 · see citing works
The Role of Inositols in the Hyperandrogenic Phenotypes of PCOS: A Re-Reading of Larner’s Results
Fedeli, V., Catizone, A., Querqui, A., Unfer, V., & Bizzarri, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076296 · Cited by 24 · see citing works
Myo-Inositol’s Role in Assisted Reproductive Technology: Evidence for Improving the Quality of Oocytes and Embryos in Patients With Polycystic Ovary Syndrome
Gupta, D., Khan, S., Islam, M., Malik, B. H., & Rutkofsky, I. H. (2020) · Cureus · doi:10.7759/cureus.8079 · Cited by 20 · see citing works
Engineering Bacillus subtilis Cells as Factories: Enzyme Secretion and Value-added Chemical Production
Yoshida, K., & van Dijl, J. M. (2020) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-020-0104-8 · Cited by 21 · see citing works
Alpha Lipoic Acid Efficacy in PCOS Treatment: What Is the Truth?
Guarano, A., Capozzi, A., Cristodoro, M., Simone, N. D., & Lello, S. (2023) · Nutrients · doi:10.3390/nu15143209 · Cited by 19 · see citing works
A combined treatment with myo-inositol and monacolin K improve the androgen and lipid profiles of insulin-resistant PCOS patients
Maria Concetta Musacchio, V. D. L. (2013) · Journal of Metabolic Syndrome · doi:10.4172/2167-0943.1000127 · Cited by 19 · see citing works
Comparing the Efficacy of Myo-Inositol Plus α-Lactalbumin vs. Myo-Inositol Alone on Reproductive and Metabolic Disturbances of Polycystic Ovary Syndrome
Kamenov, Z. A., Gateva, A., Dinicola, S., & Unfer, V. (2023) · Metabolites · doi:10.3390/metabo13060717 · Cited by 18 · see citing works
d -chiro-Inositol is absorbed but not synthesised in rodents
Lin, X., Ma, L., Gopalan, C., & Ostlund, R. E. (2009) · British Journal Of Nutrition · doi:10.1017/s0007114509990456 · Cited by 18 · see citing works
Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome
Lete, I., Martínez, A., Lasaga, I., Centurión, E., & Vesga, A. (2024) · Gynecological Endocrinology · doi:10.1080/09513590.2023.2301554 · Cited by 18 · see citing works
Effect of d -chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women
Artini, P. G., Obino, M. E. R., Micelli, E., Malacarne, E., Vacca, C., Papini, F., & Cela, V. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2020.1737007 · Cited by 17 · see citing works
Polycystic ovary syndrome (PCOS) and adolescence: How can we manage it?
Capozzi, A., Scambia, G., & Lello, S. (2020) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2020.04.024 · Cited by 17 · see citing works
Inositol phosphoglycan P-type in healthy and preeclamptic pregnancies
Scioscia, M., Gumaa, K. A., Whitten, M., Selvaggi, L. E., Rodeck, C. H., & Rademacher, T. W. (2007) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2007.03.016 · Cited by 17 · see citing works
The effect of inositol supplementation on blood pressure: A systematic review and meta-analysis of randomized-controlled trials
Tari, S. H., Sohouli, M. H., Lari, A., Fatahi, S., & Rahideh, S. T. (2021) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2021.06.017 · Cited by 16 · see citing works
Hyperinsulinemia is closely related to low urinary clearance of d-chiro-inositol in men with a wide range of insulin sensitivity
Villeneuve, M.-C., Ostlund, R. E., & Baillargeon, J. (2008) · Metabolism · doi:10.1016/j.metabol.2008.08.007 · Cited by 16 · see citing works
“Empiric” inositol supplementation in normal-weight non insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects
Vitagliano, A., Quaranta, M., Noventa, M., & Gizzo, S. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3662-9 · Cited by 16 · see citing works

Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · see citing works
A prospective, randomized, open label, comparative study of D-Chiroinositol with metformin in patients with polycystic ovary syndrome
Rajeshware, R. M. (2018)
Treatment may be on the horizon for polycystic ovary syndrome
Wunsch, H. (1999) · The Lancet · doi:10.1016/s0140-6736(05)75724-x
CONCERN: Does ovary need D-chiro-inositol?
Isabella, R., & Raffone, E. (2012) · Journal of Ovarian Research · doi:10.1186/1757-2215-5-14 · Cited by 67 · see citing works
THE EFFECT OF D-CHIRO INOSITOL IN LOWERING ANDROGENS LEVELS IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME
Sumayya Shabbir, M. I. S. (2020) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.3597132

Authors: Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J.-P., Dillon, P., Gunn, R. D., Allan, G., & Nestler, J. E.
Affiliations: Virginia Commonwealth University (US)
Hospital Clínico Universitario de Caracas (VE)
Université de Sherbrooke (CA)
Corresponding author: Nestler, John E.
ORCID: Baillargeon, Jean-Patrice
Dillon, Pamela
Venue: Endocrine Practice
Publisher: Elsevier BV
Published: 2002-11
Volume: 8
Issue: 6
Pages: 417-423
ISSN: 1530-891X (ISSN-L)
DOI: 10.4158/ep.8.6.417
OpenAlex: W1984371946
Cited by: 188
References: 33
Citations by year: 2026: 5 · 2025: 7 · 2024: 6 · 2023: 13 · 2022: 3 · 2021: 13 · 2020: 18 · 2019: 5 · 2018: 11 · 2017: 15 · 2016: 17 · 2015: 12 · 2014: 7 · 2013: 9 · 2012: 9
FWCI: 1.34
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Endocrine Practice (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (1r43hd035772-01)
National Center for Research Resources (M01RR000065, RR00065-37S1)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD035629, R43HD35772, R01HD35629)
Topics: Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
Keywords: D-chiro-inositol, polycystic ovary syndrome, insulin sensitivity, insulin resistance, free testosterone, serum androgens, ovulation, insulin sensitizers, metabolic syndrome, blood pressure, hypertriglyceridemia, lean women
MeSH terms: Adolescent, Adult, Blood Glucose, Blood Pressure, Double-Blind Method, Female, Glucose Tolerance Test, Humans, Inositol Phosphates, Insulin, Insulin Antagonists, Placebos, Polycystic Ovary Syndrome, Polysaccharides, Testosterone, Triglycerides, Body Mass Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks